Alcohol consumption and prognosis in patients with left ventricular systolic dysfunction after a myocardial infarction  by Aguilar, David et al.
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OBJECTIVES We assessed the influence of alcohol intake on the development of symptomatic heart failure
(HF) in patients with left ventricular (LV) dysfunction after a myocardial infarction (MI).
BACKGROUND In contrast to protection from coronary heart disease, alcohol consumption has been linked
to cardiodepressant effects and has been considered contraindicated in patients with HF.
METHODS The Survival And Ventricular Enlargement (SAVE) trial randomized 2,231 patients with a
LV ejection fraction (EF)40% following MI to an angiotensin-converting enzyme inhibitor
or placebo. Patients were classified as nondrinkers, light-to-moderate drinkers (1 to 10
drinks/week), or heavy drinkers (10 drinks/week) based on alcohol consumption reported
at baseline. The primary outcome was hospitalization for HF or need for an open-label
angiotensin-converting enzyme inhibitor. Analyses were repeated using alcohol consumption
reported three months after MI.
RESULTS Nondrinkers were older and had more comorbidities than light-to-moderate and heavy
drinkers. In univariate analyses, baseline light-to-moderate alcohol intake was associated with
a lower incidence of HF compared with nondrinkers (hazard ratio [HR] 0.71; 95% confidence
interval [CI] 0.57 to 0.87), whereas heavy drinking was not (HR 0.91; 95% CI 0.67 to 1.23).
After adjustment for baseline differences, light-to-moderate baseline alcohol consumption no
longer significantly influenced the development of HF (light-to-moderate drinkers HR 0.93;
95% CI 0.75 to 1.17; heavy drinkers HR 1.25; 95% CI 0.91 to 1.72). Alcohol consumption
reported three months after the MI similarly did not modify the risk of adverse outcome.
CONCLUSIONS In patients with LV dysfunction after an MI, light-to-moderate alcohol intake either at
baseline or following MI did not alter the risk for the development of HF requiring
hospitalization or an open-label angiotensin-converting enzyme inhibitor. (J Am Coll
Cardiol 2004;43:2015–21) © 2004 by the American College of Cardiology Foundationp
t
s
a
a
c
i
a
p
t
p
p
s
p
A
a
a
r
r
Vlcohol consumption appears to have both beneficial and
dverse cardiac effects. Multiple observational studies have
emonstrated a protective effect of light-to-moderate alco-
ol consumption on overall mortality, with a benefit largely
erived from a reduction in fatal coronary heart disease
1–4). This benefit has also been demonstrated in studies of
atients with known coronary artery disease (CAD) (5–7),
lthough not all studies in this population have been positive
8).
In contrast, the consumption of excessive amounts of
lcohol is a well-known cause of congestive cardiomyopathy
9), with some degree of cardiac dysfunction seen in up to
ne-third of patients with chronic alcoholism (10). In these
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edical Center, Miami, Florida; and **University of Montreal, Montreal, Canada.
he SAVE trial was originally sponsored by Squibb, Inc.
Manuscript received August 27, 2003; revised manuscript received December 17,i003, accepted January 13, 2004.atients with alcohol-induced cardiac dysfunction, reduc-
ion of alcohol intake is a crucial component of therapy, as
everal studies have shown that major clinical improvement
nd normalization of left ventricular (LV) function can be
chieved after abstention (11,12).
Given the demonstrated risks and benefits of alcohol
onsumption, the effects of continued alcohol consumption
n patients who have LV systolic dysfunction following an
cute myocardial infarction (MI) are unclear. With the
otential for CAD progression and possible re-infarction,
hese patients may derive a significant benefit from the
rotective effects of alcohol consumption; alternatively,
atients with preexisting LV dysfunction may be more
usceptible to the cardiotoxic effects of alcohol. Given this
otential risk, the American College of Cardiology/
merican Heart Association Guidelines for the Evaluation
nd Management of Chronic Heart Failure (13) state that
lcohol consumption should be avoided in patients at high
isk for the development of chronic heart failure (HF). In a
etrospective exploratory analysis, we used the Survival And
entricular Enlargement (SAVE) trial to examine thenfluence of alcohol consumption in a cohort of patients
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HF and Alcohol Consumption Post-MI June 2, 2004:2015–21ho were at high risk for the development of chronic HF
nd its complications after sustaining an MI.
ETHODS
nrollment and data collection. The database used for
his investigation was that of the SAVE trial, whose design
14) and primary analysis (15) have been described in detail.
riefly, SAVE was a randomized, multicenter double-blind
lacebo controlled trial in 2,231 patients conducted in 45
enters in the U.S. and Canada between 1987 and 1992.
his trial was designed to test the hypothesis that the
ong-term administration of an angiotensin-converting en-
yme inhibitor (captopril) to survivors of acute MI with
educed systolic function would lessen deterioration in
ardiac performance and thereby improve both mortality
nd other clinical outcomes. Patients 21 to 80 years of age
ith a LV ejection fraction of 40% or less, as measured by
adionuclide ventriculography, who survived a minimum of
hree days after a confirmed acute MI were eligible for
nrollment. All patients provided informed consent.
Upon entry into the SAVE trial, participants were asked
o classify their pattern of alcohol use three weeks before MI
nto five categories: 0, 1 to 4, 5 to 10, 11 to 20, and 20
rinks/week. Outpatient visits were then scheduled two
eeks after randomization, at intervals of three months
uring the first year, and at intervals of four months during
he remainder of the trial. At these visits, participants were
gain asked to classify their pattern of alcohol use since their
ast visit. For the purpose of our study, patients were
lassified as nondrinkers (0 drinks/week), light-to-moderate
rinkers (1 to 10 drinks/week), and heavy drinkers (10
rinks/week).
In addition to analyses using the level of alcohol con-
umption reported at baseline, we performed analyses using
lcohol consumption reported three months after the index
I in order to determine the association of continued
lcohol consumption on the development of HF. There was
moderate correlation between individual alcohol con-
umption reported at three months and the level reported at
and 12 months (Spearman coefficient 0.67 and 0.58,
espectively, p  0.001 for both). This correlation was
Abbreviations and Acronyms
CAD  coronary artery disease
CI  confidence interval
CV  cardiovascular
HF  heart failure
HR  hazard ratio
LV  left ventricular
MI  myocardial infarction
NYHA  New York Heart Association
SAVE  Survival And Ventricular Enlargement trial
SOLVD  Studies Of Left Ventricular Dysfunctionlightly stronger than the correlation between alcohol con- cumption at baseline and at 6 and 12 months (Spearman
oefficient 0.55 and 0.58, respectively, p  0.001 for both).
In addition to drinking status, other baseline variables
ere assessed, including age, gender, hypertension, body
ass index (calculated from self-reported weight and
eight), and LV ejection fraction as measured by radionu-
lide ventriculography. Patients were also classified into
roups based on smoking status, New York Heart Associ-
tion (NYHA) functional classification (I to IV), Killip
lass, history of diabetes mellitus, baseline medication use,
nd treatment (captopril) assignment.
efinition of end points. The primary outcome of this
nalysis was the development of chronic HF, defined as the
ccurrence of HF requiring hospitalization or requiring the
se of open-label angiotensin-converting enzyme inhibitors
or symptomatic treatment. Additional outcomes included
otal mortality, combined HF and total mortality, recurrent
I, and cardiovascular (CV) mortality. Myocardial infarc-
ion was identified by the primary investigator or the
ortality Classification Committee and was independently
eviewed to confirm elevated creatine kinase levels, which
ere considered positive if the levels were two times the
pper limit of normal in the absence of positive results for
he myocardial isoform or 1.5 times the upper limit in the
resence of the myocardial isoform. Cardiovascular mortal-
ty included death from atherosclerotic heart disease (death
esulting from LV dysfunction, acute MI, sudden death,
nd cardiac procedures) and other vascular causes. The
ortality Classification Committee assigned the causes of
eath based on blinded review.
tatistical analysis. Age, LV ejection fraction, and body
ass index were analyzed as continuous variables and are
resented as mean  SD. Global differences in baseline
emographics among the three alcohol usage subgroups
ere ascertained using chi-square tests for ordinal data and
ne-way analysis of variance for continuous variables. The
ifferences in the crude incidence of cardiovascular out-
omes were also compared with chi-square tests. Two-sided
alues of p  0.05 were considered significant.
Cox proportional hazards models were used to assess the
ssociation between alcohol consumption and the outcome
f interest. A univariate and a multivariate model were
reated to identify both the unadjusted and adjusted risk of
he outcome of interest. The multivariate model included
ge, gender, LV ejection fraction, prior MI, history of
ypertension, history of diabetes mellitus, body mass index,
rior tobacco use, NYHA functional classification, Killip
lass, beta-blocker use at time of randomization, thrombo-
ytic therapy with qualifying MI, and treatment (captopril)
ssignment. As described earlier, analyses were performed
sing alcohol consumption at baseline and repeated using
lcohol consumption reported 3 months following the index
I. In the model using self-reported alcohol consumption
t 3 months, only end points of interest that occurred after
0 days from enrollment (after the ascertainment of alcohol
onsumption information) were included. Patients who had
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June 2, 2004:2015–21 HF and Alcohol Consumption Post-MIeveloped the end point of interest before 90 days from
nrollment were excluded from the specific analysis.
Further analyses were performed using a Cox propor-
ional hazards model and the reported categories of alcohol
onsumption time-varying variables.
ESULTS
aseline characteristics. At initial enrollment, the pattern
f alcohol consumption was available in 2,228 of the total
,231 participants of the SAVE trial. The majority of
articipants were nondrinkers (n  1,276, 57%) with a
ignificant percentage of light-to-moderate drinkers (n 
17, 32%) and a smaller percentage of heavy drinkers (n 
35, 11%). The baseline demographics in the three groups
re described in Table 1. At baseline, nondrinkers were
lder, more likely to be women, less likely to be smokers,
nd had a higher incidence of prior MI, diabetes mellitus,
nd hypertension. In addition, nondrinkers had a higher
ody mass index, NYHA functional classification, and
illip class, and were less likely to receive thrombolytic
herapy in association with their qualifying MI.
evelopment of HF. A total of 456 patients developed
F during a mean follow-up of 42 months. The crude
ncidence of HF was 22.5% in nondrinkers, 16.6% in
ight-to-moderate drinkers, and 21.3% in heavy drinkers. In
nivariate analysis, the risk of the development of HF was
ower in the light-to-moderate drinkers compared with
ondrinkers (hazard ratio [HR] 0.71, 95% confidence in-
erval [CI] 0.57 to 0.87, p  0.01). The unadjusted HR for
eavy drinkers was not statistically different from nondrink-
Table 1. Characteristics of SAVE Participants
Reported at Baseline
Characteristics
Nondrink
(n  1,2
Age (yrs)* 60  1
Women (%)* 296 (23
Mean EF  SD 31.0  6
Previous MI (%)* 487 (38
History of diabetes mellitus (%)* 376 (29
History of hypertension (%)* 575 (45
Current smoker (%)* 496 (39
Body mass index (kg/m2)  SD* 27.2  5
NYHA (%)*
Class I 783 (61
Class II/III/IV 493 (39
Killip class  2 (%)† 525 (41
Thrombolytic therapy (%)* 384 (30
Medication use within 24 h of
randomization (%)
Aspirin 741 (60
Beta-blockers 441 (36
Treatment (captopril) (%) 624 (49
*p  0.01; †p  0.04.
EF  ejection fraction; MI  myocardial infarction; N
Ventricular Enlargement trial.rs. After adjusting for baseline differences in age, gender, cV ejection fraction, prior MI, history of hypertension,
istory of diabetes mellitus, body mass index, current
obacco use, NYHA functional classification, Killip class,
eta-blocker use at time of randomization, thrombolytic
herapy with qualifying MI, and treatment assignment, the
isk of developing HF was similar in the three groups
Table 2).
econdary end points. As described in Table 2, the unad-
usted and adjusted HRs for death, recurrent MI, and CV
eath were not statistically different among nondrinkers,
ight-to-moderate drinkers, and heavy drinkers. Compared
ith nondrinkers, light-to-moderate drinkers had a lower
rude incidence of the combined end point of death or HF,
ith an unadjusted HR of 0.78 (95% CI 0.66 to 0.91), but
he risk reduction was no longer statistically significant after
djustment for baseline differences. Additionally, no statis-
ical difference was noted in the combined end point of
eath and HF between heavy drinkers and nondrinkers.
lcohol consumption post-MI and outcomes. At the
cheduled follow-up assessment two weeks post-MI, the
attern of alcohol intake had changed, with a substantial
ncrease in the total number of nondrinkers (84%) and a
eduction of both light-to-moderate drinkers (15%) and
eavy drinkers (1%). At three months post-MI, alcohol
onsumption information was available for 2,036 patients.
mong these patients, 71% (n  1,437) were nondrinkers,
6% (n  532) were light-to-moderate drinkers, and 3% (n
67) were heavy drinkers. Of the 195 patients without
lcohol consumption information, 120 had died, two were
ost to follow-up, and 73 had no information regarding
rding to Level of Alcohol Consumption
Light-to-Moderate
Drinkers
(n  717)
Heavy Drinkers
(n  235)
59  11 55  11
90 (13) 4 (1.7)
31.0  6.6 31.2  6.9
247 (34) 757 (24)
96 (13) 20 (8.5)
260 (36) 95 (40)
289 (40) 138 (59)
26.5  4.2 26.4  4.6
502 (70) 184 (78)
215 (30) 51 (22)
257 (36) 101 (43)
264 (37) 82 (35)
432 (63) 135 (60)
255 (38) 92 (40)
366 (51) 124 (53)
 New York Heart Association; SAVE  Survival AndAcco
ers
76)
0
)
.7
)
)
)
)
.1
)
)
)
)
)
)
)
YHAontinued alcohol intake. Overall, the general pattern of
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HF and Alcohol Consumption Post-MI June 2, 2004:2015–21lcohol consumption in the cohort appeared to stabilize at
he three-month visit (Fig. 1).
Using only end points that occurred after 90 days follow-
ng enrollment, 316 patients developed HF. The unadjusted
R for the development of HF was lower in light to-
oderate drinkers (HR 0.70, 95% CI 0.53 to 0.91) com-
ared with nondrinkers, but after adjustment for baseline
ifferences, the difference was no longer statistically signif-
cant (Table 3). No statistically significant hazard was found
Table 2. Baseline Alcohol Consumption and A
Nondrinkers
(n  1,276)
Heart failure
Number (%) 287 (22.5)
Unadjusted HR (95% CI) Reference
Adjusted HR (95% CI)† Reference
Total mortality
Number (%) 300 (23.5)
Unadjusted HR (95% CI) Reference
Adjusted HR (95% CI) Reference
Mortality/heart failure
Number (%) 468 (36.7)
Unadjusted HR (95% CI) Reference
Adjusted HR (95% CI) Reference
Recurrent MI
Number (%) 175 (13.7)
Unadjusted HR (95% CI) Reference
Adjusted HR (95% CI) Reference
Cardiovascular mortality
Number (%) 249 (19.5)
Unadjusted HR (95% CI) Reference
Adjusted HR (95% CI) Reference
*p  0.01. †Model includes age, gender, left ventricular
hypertension, history of diabetes mellitus, body mass index, to
beta-blocker use at the time of randomization, thrombolytic
(captopril) assignment.
CI  confidence interval; HR  hazard ratio.
igure 1. Composition of cohort at baseline and at follow-up visits
ccording to level of reported alcohol consumption. Gray bars  heavy
rinkers, white bars  light-to-moderate drinkers, black bars  non-drinkers.n heavy drinkers, although the number of participants in
his category was small. The development of the secondary
utcomes using alcohol consumption reported three months
ost-MI are shown in Table 3.
Findings were similar when alcohol consumption was
odeled as a time-varying variable in a Cox proportional-
azards model. For both the outcomes of HF and the
ombined outcome of HF and total mortality, light-to-
oderate alcohol consumption was associated with a lower
nadjusted hazard ratio (HR 0.74 [95% CI 0.59 to 0.94]
nd HR 0.76 [95% CI 0.63 to 0.91], respectively), but after
djustment for the variables in the previous model de-
cribed, the benefit was no longer present (HR 1.02 [95%
I 0.80 to 1.31]; HR 0.99 [95% CI 0.82 to 1.19]). Using
ime-varying analyses, no statistically significant benefit or
azard was seen in heavy drinkers for the outcomes of HF
nd the combined outcome of HF and total mortality in
oth unadjusted (HR 0.78 [95% CI 0.54 to 1.14] and HR
.84 [95% CI 0.63 to 1.10], respectively) and adjusted
odels (HR 1.15 [95% CI 0.78 to 1.71] and HR 1.13 [95%
I 0.84 to 1.51], respectively).
ISCUSSION
n a group of survivors with LV dysfunction after MI,
ight-to-moderate alcohol consumption both at baseline and
hree months after the MI did not increase the risk of
hronic HF, defined as hospitalization for HF or need for
n open-label angiotensin-converting enzyme inhibitor.
he unadjusted risk of HF was lower in light-to-moderate
se Cardiovascular Outcomes
Light-to-Moderate
Drinkers
(n  717)
Heavy Drinkers
(n  235)
119 (16.6) 50 (21.3)
0.71 (0.57–0.87)* 0.91 (0.67–1.23)
0.93 (0.75–1.17) 1.25 (0.91–1.72)
150 (20.9) 51 (21.7)
0.87 (0.72–1.06) 0.91 (0.67–1.22)
1.04 (0.85–1.28) 1.19 (0.87–1.62)
213 (29.7) 84 (35.7)
0.78 (0.66–0.91)* 0.94 (0.75–1.19)
0.97 (0.82–1.15) 1.22 (0.95–1.56)
95 (13.2) 33 (14.0)
0.94 (0.74–1.21) 1.03 (0.71–1.49)
1.11 (0.86–1.44) 1.34 (0.91–1.97)
129 (18.0) 42 (17.9)
0.90 (0.73–1.12) 0.90 (0.65–1.25)
1.10 (0.88–1.37) 1.16 (0.82–1.64)
on fraction, prior myocardial infarction (MI), history of
use, New York Heart Association classification, Killip class,
py with the qualifying myocardial infarction, and treatmentdver
ejecti
bacco
therarinkers compared with nondrinkers but, after adjustment
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June 2, 2004:2015–21 HF and Alcohol Consumption Post-MIor significant baseline differences between the two groups,
he HR was no longer statistically significant, suggesting
hat the additional comorbidities in the nondrinkers may
ave accounted for the results. Additionally, light-to-
oderate alcohol consumption was neither beneficial nor
etrimental in the outcomes of total mortality, total mor-
ality and/or HF, recurrent MI, and CV mortality. No
ignificant benefit or risk was associated with heavy alcohol
se, but the low number of individuals and events in this
roup prohibit definitive conclusions.
lcohol consumption, coronary heart disease, and HF.
revious studies in populations free of CV disease have
emonstrated an approximately 20% to 30% reduction in
otal mortality associated with light-to-moderate alcohol
onsumption (1–4). The benefit is largely related to a
eduction in coronary heart disease in light-to-moderate
rinkers compared with nondrinkers. Potential mechanisms
or this finding include the beneficial effects of alcohol on
igh-density lipoprotein cholesterol (16–18), platelet acti-
ation (19), and hemostatic markers (20).
In studies of patients with known CAD, the beneficial
ffects of alcohol consumption have been less conclusive.
lthough most studies have demonstrated that patients
ith a history of prior MI derive a benefit with light-to-
oderate alcohol consumption (5–7), additional studies (8),
ncluding this study of the SAVE population, have failed to
emonstrate a significant benefit in secondary prevention.
The influence of alcohol consumption on the develop-
ent of HF is unclear in both the general population and
hose with known CAD. Several case-control series have
Table 3. Level of Alcohol Consumption Repo
Cardiovascular Outcomes
Nondrinkers
Heart failure
Number (%) 237/1,355 (17.
Unadjusted HR (95% CI) Reference
Adjusted HR (95% CI)† Reference
Total mortality
Number (%) 274/1,437 (19.
Unadjusted HR (95% CI) Reference
Adjusted HR (95% CI) Reference
Mortality/heart failure
Number (%) 386/1,355 (28.
Unadjusted HR (95% CI) Reference
Adjusted HR (95% CI) Reference
Recurrent MI
Number (%) 145/1,391 (10.
Unadjusted HR (95% CI) Reference
Adjusted HR (95% CI) Reference
Cardiovascular mortality
Number (%) 215/1,437 (15.
Unadjusted HR (95% CI) Reference
Adjusted HR (95% CI) Reference
*p  0.01; ‡p  0.04. †Model includes age, gender, left vent
of diabetes mellitus, body mass index, tobacco use, New Yor
the time of randomization, thrombolytic therapy with the q
Abbreviations as in Table 2.inked excessive alcohol consumption to a dilated cardiomy- fpathy (9,10,21). Although the exact mechanism is un-
nown, the quantity (10) and duration of alcohol use (22)
ppear to play a role in the development of LV dysfunction.
mportantly, the cessation of alcohol consumption is crucial,
s continued excessive alcohol consumption carries an ad-
erse prognosis (23,24) and the cessation of alcohol intake
ay lead to improvement in LV function (11,12).
In contrast to these smaller case-control studies, two large
ohort studies of individuals free of HF at baseline have
ailed to demonstrate an association between alcohol con-
umption and increased risk of HF (25,26). In fact, light-
o-moderate alcohol consumption lowered the HR for the
evelopment of HF in both studies (25,26). In these studies,
he effect of alcohol consumption on the development of
F was independent of the development of recurrent MI,
uggesting that, in addition to its effects on CAD, alcohol
onsumption was reducing the development of HF through
dditional pathways such as a reduction in hypertension
27,28) or beneficial neurohormonal modification (29,30).
mportantly, these studies have been limited to those who
ere free of HF at baseline.
Few studies have examined the influence of continued
lcohol consumption on the development of HF in patients
ith LV dysfunction after an MI. In the Studies Of Left
entricular Dysfunction Prevention and Treatment trials
SOLVD) database, which excluded patients with a recent
I, light-to-moderate alcohol consumption in participants
ith ischemic cardiomyopathy was associated with a re-
uced crude incidence of hospitalization for HF, but,
imilar to our study, after adjustment for potential con-
hree Months Post MI and Adverse
Light-to-Moderate
Drinkers
Heavy
Drinkers
69/516 (13.4) 10/64 (15.6)
0.70 (0.53–0.91)* 0.81 (0.43–1.52)
0.93 (0.71–1.23) 1.21 (0.64–2.31)
74/532 (13.9) 7/67 (10.5)
0.69 (0.54–0.90)* 0.48 (0.23–1.02)
0.91 (0.70–1.19) 0.66 (0.31–1.41)
109/516 (21.1) 12/64 (18.8)
0.69 (0.55–0.85)* 0.60 (0.34–1.06)
0.88 (0.71–1.10) 0.85 (0.47–1.52)
50/524 (9.5) 8/64 (12.5)
0.89 (0.64–1.22) 1.10 (0.54–2.24)
1.04 (0.75–1.46) 1.30 (0.63–2.67)
62/532 (11.7) 7/67 (10.4)
0.74 (0.56–0.99)‡ 0.62 (0.29–1.32)
1.00 (0.75–1.34) 0.87 (0.40–1.87)
ejection fraction, prior MI, history of hypertension, history
rt Association classification, Killip class, beta-blocker use at
g MI, and treatment (captopril) assignment.rted T
5)
1)
5)
4)
0)
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ualifyinounders the benefit was no longer statistically significant
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HF and Alcohol Consumption Post-MI June 2, 2004:2015–2131). In SOLVD, HF progression was not increased with
ight-to-moderate alcohol consumption in patients with
schemic LV dysfunction, although there was a trend toward
ncreased risk of HF hospitalization in those participants
ith nonischemic LV dysfunction. Additionally, in the
OLVD database, light-to-moderate alcohol intake was
ssociated with a reduction in total mortality, a finding not
emonstrated in our study, perhaps related to differences in
atient populations. In contrast, in a study of 753 patients
dmitted to a Veterans Administration facility with HF, the
ajority of whom had nonischemic LV dysfunction, alcohol
onsumption was an independent predictor of multiple
eadmissions for HF (32). Additionally, a study of alcohol
onsumption in 396 patients with nonischemic LV dysfunc-
ion demonstrated a hazard in women, but not in men (33).
Some potential limitations of this analysis should be
oted. First, the amount of alcohol consumption is self-
eported without specific information regarding the exact
uantity, type of alcoholic beverage, or pattern of alcohol
onsumption. However, prior studies have found that self-
eporting can provide reliable estimates of alcohol intake
34), and several studies have suggested that the effects of
lcohol consumption may be similar across different types of
lcoholic beverages (35,36). Additionally, the category of
eavy drinkers includes individuals who may have met the
.S. Dietary Guidelines for moderate drinking (two drinks/
ay in men) (37). Because the enrollment and follow-up
uestionnaires grouped individuals reporting 10 to 20
rinks/week together, we could not distinguish these indi-
iduals with moderate alcohol intake from those with
eavier alcohol consumption. Finally, the sample size does
ot allow us to definitively exclude a small hazard of
ight-to-moderate alcohol consumption on the development
f HF and, importantly, the small number of heavy drinkers
imits the ability to draw conclusions regarding this cate-
ory.
onclusions. In survivors of an MI with depressed LV
unction, light-to-moderate alcohol consumption reported
t baseline or three months following the MI was associated
ith a lower crude incidence of subsequent HF and the
ombined outcome of HF and total mortality, a finding that
ppeared to be explained by the greater comorbidity in the
ondrinkers compared with light-to-moderate drinkers.
fter adjustment for potential confounders, our study dem-
nstrated neither a benefit nor excess hazard associated with
ight-to-moderate alcohol consumption. Careful note
hould be made that the small number of heavy drinkers
imits the ability to draw definitive conclusions from this
ubset.
Because of ethical and practical considerations, a ran-
omized controlled trial of alcohol consumption is not
easible. Therefore, future observational studies will need to
xamine the issue of alcohol use in patients with reduced LV
unction and CAD. Although the limited data available
upport continued discouragement of heavy alcohol use in
his population, the totality of evidence suggests that light-o-moderate alcohol consumption is not associated with
ltered risk of developing chronic HF in patients with LV
ysfunction following MI.
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